MedTrace Logo

Neuroinflammation and Modulating Factors in Depression and HIV

NCT04286282 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2025-01-09

Study results available
· View outcomes & findings →

Summary

Determine if depression, which persists after depression treatment at 26 weeks, is associated with increased innate inflammation in a prospective cohort of HIV-infected Ugandans receiving SSRIs in which group psychotherapy is initiated.

Conditions

Interventions

BEHAVIORAL

Group Pyschotherapy

Group psychotherapy

OTHER

Depression Standard of Care

Standard clinical care for depression, which may include the use of selective serotonin re-uptake inhibitors (SSRIs).

OTHER

HIV Standard of Care

Standard clinical care for HIV

Sponsors & Collaborators

Principal Investigators

  • Sarah Lofgren, MD · University of Minnesota

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2023-11-09
Completion
2024-04-09

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04286282 on ClinicalTrials.gov